Browsing by Author "ferhat ekinci"
Now showing 1 - 9 of 9
Results Per Page
Sort Options
Item Effects of Nutritional Support on the Quality of Life of Cancer Patients(2022) ATIKE PINAR ERDOGAN; ferhat ekinci; Gamze GOKSEL; Gülnur kösem; Melek ÇiviObjective: In this study, we investigated the effects of nutritional support on the quality of life of cancer patients, determined nutritional deficiencies, eliminated it at the earliest, and established a built-in system to prolong patient survival. Material and Methods: We included 459 patients admitted to the medical oncology outpatient clinic, diagnosed with cancer and receiving chemotherapy; 59 of 459 patients were diagnosed with malnutrition in the study using the Nutritional Risk Screening (NRS) 2002 nutritional status scale. Appropriate enteral nutrition support was provided to the patients, and control evaluations were made four times at intervals of 28 days. In these controls, information on the height, weight, and the right and left middle arm circumference of the patients was recorded. Along with the European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-30 (EORTC QLQ-30) Quality of Life Scale, the Hospital Anxiety and Depression Scale was also used. Results: A statistically significant difference was found in the NRS 2002 scores of the patients regarding the adequacy of intake, protein and calorie requirement, functional status, and the symptom scale. The anxiety and depression scores of the patients decreased in all the controls, and the most noticeable decrease occurred at the end of the third control. Conclusion: Evaluating malnutrition and providing adequate nutritional support to cancer patients improves body composition and the quality of life by reducing anxiety and depression.Item Vinorelbine Induced Serpentine Supravenous Hyperpigmentation(2022) Ahsen Duygu YETUT; Ahmet Dirican; Cumali ÇELİK; ATIKE PINAR ERDOGAN; SEMRA TAŞ; ferhat ekinciSerpentine supravenous hyperpigmentation (SSH) is a rare complexity arising from antineoplastic therapy. Vinorelbine, a\rchemotherapeutic drug that is frequently used for the treatment of breast and lung cancer, contributes to the etiology of SSH. A 54 years old\rmale patient was being treated for lung adenocarcinoma. An intravenous (IV) infusion of vinorelbine was administered in the distal dorsal vein\rof the left forearm. Erythematous hyperpigmentation at the infusion area was observed a week after the administration of the chemotherapeutic\rdrug. The initial symptoms of SSH usually appear between 1 to 15 days post IV administration of a cytotoxic drug, and it spontaneously becomes\rhyperpigmented within 1-3 weeks. However, these local reactions can be prevented by applying IV infusion for a short period (15-30\rmin) along with adequate venous irrigation (75-124 mL) instead of bolus administration. The termination of the drug can also be considered.Item Can Albumin Bilirubin Ratio Predict Survival in Metastatic \rGastric Cancer?(2022) ferhat ekinci; ATIKE PINAR ERDOGANObjectives: This study evaluated the prognostic significance of the new index designed with albumin and bilirubin ratio (ABR) in patients with metastatic gastric cancer (GC).\rMethods: The data of patients with metastatic gastric cancer followed in the medical oncology clinic between February 2012, and May 2020 were retrospectively reviewed. ABR was defined by dividing the albumin level by the bilirubin level.\rResults: Overall survival (OS) of all patients was reported as 12.9 months (95% CI, 10.9-14.9). The effect of ABR on survival time was not found statistically significant (p=0.462; p>0.05).\rConclusion: This study evaluated the prognostic significance of the new index designed with ABR in patients with metastatic gastric cancer (GC), but no statistically significant result was obtained. Simple, accessible, and inexpensive tests showing recurrence, treatment response, and prognosis of GC are needed. Studies should be conducted with a more significant number of patient populations to determine the role of ABR in GCItem Predictive Value of Lymphocyte-Related Blood Parameters of\rbefore Ado-Trastuzumab Emtansin Treatment in Breast Cancer(2022) ATIKE PINAR ERDOGAN; cengiz yilmaz; Serkan Yıldırım; ferhat ekinci; Gulcan Bulut; Ahmet ÖzverenObjective: Ado-Trastuzumab Emtansine ( TDM1) has been used in the treatment of HER2 metastatic breast cancer after\rFDA approval as an antibody-drug conjugate. Some markers may be predictive for clinician in the management of this\rTDM1 therapy. There is a need for simple and cost-effective markers to show the treatment response. The primary aim\rof this study is to establish a correlation between progression free survival and pre-treatment hematological inflammatory\rparameters [absolute lymphocyte count (ALC), neutrophil-to-lymphocyte ratio (NLR), and platelet-lymphocyte\rratio (PLR)] in advance breast cancer.\rMethods: Forty-one female patients with metastatic HER-2 positive breast cancer who received TDM-1 between 2016\rand 2021 were evaluated retrospectively. NLR and PLR were calculated with the values of neutrophils, lymphocytes,\rand trombocytes in complete blood count at the time of diagnosis. The cut off values of NLR and PLR were determined\rusing receiver operating characteristic (ROC) curve analysis. Overall survival (OS) and progression free survival (PFS)\rassociated with prior treatment NLR, PLR, ALC were performed by Kaplan-Meier method.\rResults: Median age was 49.5 years years (26-76).Patients divided into 2 groups according to NLR cut-off and TLR cutoff\rvalues as NLR/TLR high and low groups. The cut-off values of NLR and TLR were 144.0, and 2.74, respectively. ALC\rdivided into 2 groups. There was no significant difference in OS between NLR ,PLR,ALC (high/low) groups. (p=0.04, 0.15,\r0.53 respectively). There was only significant difference in PFS (high/low) groups.(p=0.81, 0.99, 0.96 respectively).\rConclusions: The predictive value of pre-treatment only NLR on the therapeutic potential in patients with metastatic\rbreast cancer treated with TDM1.Item Timik Metastaz ile Prezente Olan Meme Karsinomu: Bir Olgu Sunumu(2023) emine bihter eniseler; ferhat ekinci; FATMA CAN; ATIKE PINAR ERDOGAN; Gamze GOKSELTimus, superior ve anterior mediastinumda yerleşik primer lenfoid bir organdır. Anterior mediastinal tümörlerin neredeyse tamamını timik tümörler oluşturmaktadır. Timomalar, erişkinlerde timusun en sık görülen tümörleri olmakla birlikte, timusa bir tümörün metastazı oldukça nadirdir. Timustaki yer kaplayan oluşumların tanısı sıklıkla klinik ve radyolojik bulgular ile konur ve histopatolojik inceleme ile kesinleşmektedir. Bu yazıda mastektomi sonrası 9. yılda soliter timus metastazı gözlenen meme kanseri tanılı bir olgu sunulmaktadır.Item Chemotherapy Choice in Neoadjuvant Dual Her2 Blockade: Is it Really Essential to Add Anthracycline?(2023) ferhat ekinci; Kutay Kırdök; ATIKE PINAR ERDOGAN; Ahmet Özveren; Elvina Almuradova; Bulent KarabulutObjectives: Addition of trastuzumab and pertuzumab to neoadjuvant chemotherapy in Human epidermal growth factor receptor 2 (HER-2) positive breast cancer is the current clinical standard. We aimed to determine whether anthra- cycline-containing neoadjuvant chemotherapy yields beneficial effects alongside dual HER-2 blockade, and to assess cardiotoxicity with this treatment. Methods: Fifty-two patients with HER-2-positive breast cancer who received neoadjuvant chemotherapy were ret- rospectively evaluated at three tertiary health-care centers. The effects of chemotherapy regimen and several other factors such as age, stage, menopause status, lymph node positivity, and hormone receptor positivity on pathological complete response (pCR) were evaluated. Results: The mean age at diagnosis was 46±9 years. The pCR rate was similar between those with and without anthra- cycline-containing regimens (71.4% vs. 70%). Subgroup analyses also showed similar pCR values for those with nega- tive and positive hormone receptors (64.7% vs. 74.3%), those with Ki67 levels <20% and >20% (60% vs. 73.8%), and when premenopausal patients were compared with postmenopausal patients (76.9% vs. 65.4%). Conclusion: It appears that adding anthracycline to dual HER-2 blockade for neoadjuvant therapy did not yield addi- tional benefits in terms of pCR. Further studies are needed to assess anthracycline-containing regimens in patients who will use the neoadjuvant pertuzumab-trastuzumab combination.Item Real-Life Data of Neoadjuvant Chemotherapy in Breast Cancer: Aegean Region Experience(2023) ferhat ekinci; Ahmet Özveren; emine bihter eniseler; Bilgin Demir; Mustafa Şahbazlar; ATIKE PINAR ERDOGANObjective: The use of neoadjuvant chemotherapy (NACT) in breast cancer is increasing. However the management of locally advanced breast cancer differs due to the approach of the center to which the patient applied and the approach of the following physician. From this point of view, we aimed to evaluate the real life data of our region. Methods: The study included 106 patients treated with NACT in the medical oncology clinic of two different university hospitals. Association between clinicopathological features and pathological complete response (pCR) were analyzed. Results: The pCR rate was higher in patients with negative hormone receptors and this difference was statistically significant (p:0.000). The rate of obtaining pCR increased as the NACT duration increased, and this increase was statistically significant. The mean NACT duration applied to the patients with pCR was 5.48 ± 0.22 months, and the mean NACT duration for those who could not obtain pCR was 5.01 ± 0.1 months (p:0.041). The recurrence rate of patients with pCR was 11.1%, while the recurrence rate of patients who could not obtain pCR was 31.6% (p:0.04). Conclusion: Pathological response to chemotherapy is an important factor in determining prognosis. There appears to be a need for new biomarkers that allow the prediction of pCR and long-term outcomes.Item Glomerulonefritlerde JAK2 Gen Mutasyonu Sıklığının Araştırılması(2023) serkan yildiz; Altug Koc; ferhat ekinci; Cengiz Ceylan; Mehmet Tanrisev; Suleyman Yildirim; Tuba Demirci Yıldırım; UTKU ERDEM SOYALTIN; Yasar Kutbay; harun akarAmaç: Glomerulonefritler (GN) patofizyolojisi tamamen anlaşılamamış bir grup heterojen hastalıktır. Bu çalışmanın amacı GN hastalarında Janus kinase (JAK)2 mutasyon sıklığının araştırılmasıdır. Yöntem: Bu çalışma Mayıs 2015 ve Ekim 2015 tarihleri arasında Sağlık Bilimleri Üniversitesi İzmir Tepecik Eğitim ve Araştırma Hastanesi Nefroloji Kliniği ve Dokuz Eylül Üniversitesi Tıp Fakültesi Nefroloji Bilim Dalı'nda yapılmıştır. GN tanılı 67 hasta ve kontrol grubu olarak 100 sağlıklı gönüllü çalışmaya dahil edilmiştir. JAK2 mutasyonu genetik analizi periferik venöz kanda çalışılmıştır. Bulgular: GN grubundaki katılımcıların 33’ü erkekti (%49) ve yaş ortalaması 45,8±12,4’tü. Kontrol grubundaki katılımcıların 37’si erkekti (%37) ve yaş ortalaması 40,1±14,7’ydi. Her iki gruptaki katılımcıların hiçbirinde JAK2 mutasyonu tespit edilmedi. Sonuç: Çalışmamızda JAK2 mutasyonu ve GN arasında doğrudan bir ilişki tespit edilememiştir. JAK-sinyal transdüserleri ve transkripsiyon aktivatörleri (STAT) yolağı ile GN arasındaki ilişkinin değerlendirilmesi için özellikle doku düzeyinde olmak üzere daha fazla çalışmaya ihtiyaç vardır.Item Metastatik Pankreas Kanserinde Hemoglobin, Albümin, Lenfosit, Trombosit Skorunun Klinik Önemi(2023) onur yazdan balçık; Ali Aytaç; ferhat ekinci; Yusuf ilhan; Bilgin Demir; ATIKE PINAR ERDOGAN; Gökhan KarakayaGiriş ve Amaç: Pankreas adenokarsinomu en ölümcül kanserlerden biridir. Metastatik pankreas kanserli hastaların prognozunu tahmin etmek için günlük hayatta kullanılabilecek etkili, basit ve pratik yöntemler halen eksiktir ve prognozu tahmin etmek için umut verici bir biyobelirteç gerekmektedir. Çalışmamızda metastatik pankreas kanserinde HALP skorunun prognoz ile ilişkisini göstermeyi amaçladık. Yöntem ve Gereçler: 2016-2022 yılları arasında Türkiye'de 4 merkezden metastatik pankreas kanseri tanısı alan hastalar dahil edildi. Demografik veriler, hemogram parametreleri, biyokimya değerleri ve alınan tedaviler kaydedildi. Genel sağkalım (OS) ve progresyonsuz sağkalım (PFS) da kaydedildi. Bulgular: Çalışmamızda 280 hasta vardı. Tüm popülasyon için medyan PFS 7,53 aydı, medyan OS ise 11,53 aydı. Medyan PFS, HALP-Düşük grup için 7,1 ay ve HALP-Yüksek grup için 14,8 aydı. HALP- Düşük grubun median PFS'si HALP-Yüksek gruba göre daha kısaydı ve gruplar arasında istatistiksel olarak anlamlı bir fark vardı (p: <0,001). Tartışma ve Sonuç: Sonuç olarak, HALP skoru ucuz, pratik, literatüre katkıda bulunan bir belirteçtir ve prospektif çalışmalarla doğrulanırsa, metastatik pankreas kanseri olan hastaların prognozunu tahmin etmek için rutin klinik uygulamada kullanılabilir.